EpiVacCorona
EpiVacCorona vaccine against COVID-19 / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about EpiVacCorona?
Summarize this article for a 10 year old
EpiVacCorona (Russian: ЭпиВакКорона, tr. EpiVacCorona) is a peptide-based vaccine against COVID-19 developed by the Russian VECTOR Center of Virology.[2][3] The lack of protective effectiveness of EpiVacCorona, which is still in use in Russia, has been reported in scientific literature[4] and in the media.[5][6] The vaccine consists of three chemically synthesized peptides (short fragments of a viral spike protein) that are conjugated to a large carrier protein. This protein is a fusion product of a viral nucleocapsid protein and a bacterial MBP protein. A phase III clinical trial to show whether or not the vaccine can protect people against COVID-19 was launched in November 2020 with more than three thousand participants. The conclusions and results of the trial have not been made public.[7][8]
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Peptide subunit |
Clinical data | |
Trade names | EpiVacCorona |
Other names | EpiVacCorona-N,[1] Aurora-CoV[1] |
Routes of administration | Intramuscular |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
DrugBank |
Some experts in the field have expressed concerns about the selection of peptides for use as vaccine antigens.[9][10] In addition, there are also serious concerns about the vaccine immunogenicity data, which have fueled independent civic research efforts[11][12][13] and criticism by some experts.[9] Current Time TV reported that "EpiVacCorona's reputation declined when vaccine trial participants sent an open letter to the Ministry of Health to flag 18 cases of COVID-19 infection among their group after vaccination with EpiVacCorona, and a lack of virus antibodies".[14]